How much will Abbott pay for Exact Sciences, and how is the deal financed?

Abbott will pay $105.00 per Exact Sciences share in cash, for an equity value of roughly $21 billion and an enterprise value of about $23 billion including Exact Sciences' estimated $1.8 billion of net debt. Abbott plans to fund the transaction with a combination of cash on hand and debt, including up to $20 billion of bridge loan commitments from Morgan Stanley Senior Funding.

When is the deal expected to close, and what could prevent it?

Closing is expected in the second quarter of 2026. Completion requires approval by a majority of Exact Sciences shareholders, expiration or termination of the HSR waiting period, receipt of other specified regulatory approvals, and no legal order blocking the merger. Risks disclosed include competing offers and the possibility the merger agreement is terminated, in which case Exact Sciences may owe a termination fee.

Will the acquisition help or hurt Abbott's earnings?

In the near term it is dilutive to adjusted EPS: management estimates $0.20 per share dilution in 2026 and $0.16 in 2027. Abbott expects the transaction to be accretive in 2028 and beyond, supported by at least $100 million in annual pre-tax synergies by 2028, and expects a return to double-digit EPS growth after the dilutive period.

What does Exact Sciences contribute to Abbott's growth and margins?

Exact Sciences is expected to generate more than $3 billion in 2025 revenue, growing at a high-teens organic rate with a 70%+ adjusted gross margin. Abbott estimates the deal adds about 50 basis points to its total organic sales growth and about 100 basis points to its gross margin, with larger effects of roughly 300 and 700 basis points on its Diagnostics segment.

What is the growth opportunity behind the deal?

Abbott cites a U.S. cancer screening and precision oncology opportunity of more than $60 billion, and says the combination doubles its total addressable market in cancer diagnostics to over $120 billion. Growth drivers include Cologuard Plus, the newly launched Cancerguard multi-cancer blood test, Oncodetect for molecular residual disease monitoring, and a pipeline of blood-based screening and monitoring tests.

ABT 8-K: Material Agreements & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed November 20, 2025. Cited figures are marked; the original filing is the authoritative source.

On November 19, 2025, Abbott Laboratories (ABT) entered into a definitive Agreement and Plan of Merger to acquire Exact Sciences (EXAS), a leader in cancer screening and precision oncology diagnostics, for $105.00^a per share in cash.

The deal implies a total equity value of approximately $21 billion^b and an enterprise value of about $23 billion, including roughly $1.8 billion of Exact Sciences net debt that Abbott's financing will absorb. The transaction was unanimously approved by both boards and is expected to close in the second quarter of 2026, subject to Exact Sciences shareholder approval, HSR antitrust clearance, and other regulatory approvals. Abbott also secured a commitment letter from Morgan Stanley Senior Funding for up to $20 billion of senior unsecured bridge loans.

Strategically, Abbott is adding a high-growth vertical to its diagnostics franchise. Exact Sciences is projected to generate more than $3 billion^c in 2025 revenue with high-teens organic growth and a 70%+ adjusted gross margin profile. Management argues the deal is immediately accretive to Abbott's organic sales growth (about +50 basis points for the total company, +300 bps for Diagnostics) and gross margin (about +100 bps total, +700 bps for Diagnostics).

Abbott expects the combination to double its addressable market in cancer diagnostics to more than $120 billion^d, with at least $100 million in annual pre-tax synergies by 2028. The financial trade-off is near-term EPS dilution: management projects adjusted EPS dilution of $0.20 in 2026 and $0.16 in 2027, with accretion expected in 2028 and beyond.

Abbott expects to maintain its investment-grade credit rating and projects an initial 2026 adjusted gross debt-to-EBITDA ratio of about 2.7x after closing. Key risks include regulatory review, the Exact Sciences shareholder vote, potential competing offers, integration execution, and the possibility that expected synergies or growth are not realized.

02—Key points

Key Highlights

Abbott will acquire Exact Sciences for $105.00 per share in cash, implying a ~$21 billion equity value and ~$23 billion enterprise value including ~$1.8 billion of net debt.
Exact Sciences brings Cologuard, Oncotype DX, Oncodetect (MRD), and Cancerguard (multi-cancer detection) into Abbott, expanding its footprint in cancer screening and precision oncology.
Exact Sciences is projected to generate more than $3 billion in 2025 revenue with high-teens organic growth and a 70%+ adjusted gross margin profile.
The deal is expected to be immediately accretive to Abbott's organic sales growth (~+50 bps) and gross margin (~+100 bps), and to Diagnostics segment growth (~+300 bps) and margin (~+700 bps).
Management projects adjusted EPS dilution of $0.20 in 2026 and $0.16 in 2027, with accretion expected in 2028 and beyond and at least $100 million in annual pre-tax synergies by 2028.
Abbott has secured a commitment from Morgan Stanley Senior Funding for up to $20 billion of senior unsecured bridge loans, and expects an initial 2026 adjusted gross debt-to-EBITDA ratio of about 2.7x while maintaining an investment-grade rating.
Closing is expected in Q2 2026, subject to Exact Sciences shareholder approval, HSR clearance, other regulatory approvals, and customary conditions; both boards unanimously approved the deal.

03—Questions

Frequently Asked Questions

How much will Abbott pay for Exact Sciences, and how is the deal financed?
Abbott will pay $105.00 per Exact Sciences share in cash, for an equity value of roughly $21 billion and an enterprise value of about $23 billion including Exact Sciences' estimated $1.8 billion of net debt. Abbott plans to fund the transaction with a combination of cash on hand and debt, including up to $20 billion of bridge loan commitments from Morgan Stanley Senior Funding.
When is the deal expected to close, and what could prevent it?
Closing is expected in the second quarter of 2026. Completion requires approval by a majority of Exact Sciences shareholders, expiration or termination of the HSR waiting period, receipt of other specified regulatory approvals, and no legal order blocking the merger. Risks disclosed include competing offers and the possibility the merger agreement is terminated, in which case Exact Sciences may owe a termination fee.
Will the acquisition help or hurt Abbott's earnings?
In the near term it is dilutive to adjusted EPS: management estimates $0.20 per share dilution in 2026 and $0.16 in 2027. Abbott expects the transaction to be accretive in 2028 and beyond, supported by at least $100 million in annual pre-tax synergies by 2028, and expects a return to double-digit EPS growth after the dilutive period.
What does Exact Sciences contribute to Abbott's growth and margins?
Exact Sciences is expected to generate more than $3 billion in 2025 revenue, growing at a high-teens organic rate with a 70%+ adjusted gross margin. Abbott estimates the deal adds about 50 basis points to its total organic sales growth and about 100 basis points to its gross margin, with larger effects of roughly 300 and 700 basis points on its Diagnostics segment.
What is the growth opportunity behind the deal?
Abbott cites a U.S. cancer screening and precision oncology opportunity of more than $60 billion, and says the combination doubles its total addressable market in cancer diagnostics to over $120 billion. Growth drivers include Cologuard Plus, the newly launched Cancerguard multi-cancer blood test, Oncodetect for molecular residual disease monitoring, and a pipeline of blood-based screening and monitoring tests.

04—Continue

← View all 8-K filings